PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites

Publication

PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites

Journal Paper/Review - Dec 27, 2012

Glas Jürgen, Duerr Richard H, Franke Andre, Kamboh M Ilyas, Achkar Jean-Paul, Balschun Tobias, Müller-Myhsok Bertram, Wolf Christiane, Olszak Torsten, Wetzke Martin, Diegelmann Julia, Pasciuto Giulia, Czamara Darina, Seiderer Julia, Brand Stephan

Citation

Glas J, Duerr R, Franke A, Kamboh M, Achkar J, Balschun T, Müller-Myhsok B, Wolf C, Olszak T, Wetzke M, Diegelmann J, Pasciuto G, Czamara D, Seiderer J, Brand S. PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites. PloS one 2012; 7:e52873.

Type

Journal Paper/Review (English)

Journal

PloS one 2012; 7

Publication Date

Dec 27, 2012

Issn Electronic

1932-6203

Pages

e52873

Brief description/objective

BACKGROUND
Genome-wide association studies identified a PTGER4 expression-modulating region on chromosome 5p13.1 as Crohn's disease (CD) susceptibility region. The study aim was to test this association in a large cohort of patients with inflammatory bowel disease (IBD) and to elucidate genotypic and phenotypic interactions with other IBD genes.

METHODOLOGY/PRINCIPAL FINDINGS
A total of 7073 patients and controls were genotyped: 844 CD and 471 patients with ulcerative colitis and 1488 controls were analyzed for the single nucleotide polymorphisms (SNPs) rs4495224 and rs7720838 on chromosome 5p13.1. The study included two replication cohorts of North American (CD: n = 684; controls: n = 1440) and of German origin (CD: n = 1098; controls: n = 1048). Genotype-phenotype, epistasis and transcription factor binding analyses were performed. In the discovery cohort, an association of rs4495224 (p = 4.10×10⁻⁵; 0.76 [0.67-0.87]) and of rs7720838 (p = 6.91×10⁻⁴; 0.81 [0.71-0.91]) with susceptibility to CD was demonstrated. These associations were confirmed in both replication cohorts. In silico analysis predicted rs4495224 and rs7720838 as essential parts of binding sites for the transcription factors NF-κB and XBP1 with higher binding scores for carriers of the CD risk alleles, providing an explanation of how these SNPs might contribute to increased PTGER4 expression. There was no association of the PTGER4 SNPs with IBD phenotypes. Epistasis detected between 5p13.1 and ATG16L1 for CD susceptibility in the discovery cohort (p = 5.99×10⁻⁷ for rs7720838 and rs2241880) could not be replicated in both replication cohorts arguing against a major role of this gene-gene interaction in the susceptibility to CD.

CONCLUSIONS/SIGNIFICANCE
We confirmed 5p13.1 as a major CD susceptibility locus and demonstrate by in silico analysis rs4495224 and rs7720838 as part of binding sites for NF-κB and XBP1. Further functional studies are necessary to confirm the results of our in silico analysis and to analyze if changes in PTGER4 expression modulate CD susceptibility.